annual EBITDA:
$1.56B-$330.95M(-17.54%)Summary
- As of today (May 21, 2025), RPRX annual EBITDA is $1.56 billion, with the most recent change of -$330.95 million (-17.54%) on December 31, 2024.
- During the last 3 years, RPRX annual EBITDA has risen by +$125.99 million (+8.81%).
- RPRX annual EBITDA is now -43.49% below its all-time high of $2.75 billion, reached on December 31, 2019.
Performance
RPRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$498.69M+$98.58M(+24.64%)Summary
- As of today (May 21, 2025), RPRX quarterly EBITDA is $498.69 million, with the most recent change of +$98.58 million (+24.64%) on March 31, 2025.
- Over the past year, RPRX quarterly EBITDA has increased by +$458.74 million (+1148.01%).
- RPRX quarterly EBITDA is now -67.10% below its all-time high of $1.52 billion, reached on December 31, 2019.
Performance
RPRX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$2.02B+$458.74M(+29.48%)Summary
- As of today (May 21, 2025), RPRX TTM EBITDA is $2.02 billion, with the most recent change of +$458.74 million (+29.48%) on March 31, 2025.
- Over the past year, RPRX TTM EBITDA has increased by +$643.87 million (+46.96%).
- RPRX TTM EBITDA is now -32.55% below its all-time high of $2.99 billion, reached on September 30, 2020.
Performance
RPRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RPRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -17.5% | +1148.0% | +47.0% |
| 3 y3 years | +8.8% | +175.8% | +43.0% |
| 5 y5 years | -43.5% | +196.1% | -17.8% |
RPRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -17.5% | +267.3% | -42.9% | +188.6% | at high | +375.6% |
| 5 y | 5-year | -43.5% | +267.3% | -42.9% | +188.6% | -32.5% | +375.6% |
| alltime | all time | -43.5% | +267.3% | -67.1% | +188.6% | -32.5% | +375.6% |
RPRX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $498.69M(+24.6%) | $2.02B(+29.5%) |
| Dec 2024 | $1.56B(-17.5%) | $400.11M(-54.2%) | $1.56B(-19.0%) |
| Sep 2024 | - | $872.86M(+258.6%) | $1.92B(+57.9%) |
| Jun 2024 | - | $243.39M(+509.1%) | $1.22B(-11.3%) |
| Mar 2024 | - | $39.96M(-94.8%) | $1.37B(-27.3%) |
| Dec 2023 | $1.89B(+345.4%) | $764.84M(+355.0%) | $1.89B(+237.4%) |
| Sep 2023 | - | $168.11M(-57.8%) | $559.36M(-15.1%) |
| Jun 2023 | - | $398.29M(-28.4%) | $658.64M(-17.6%) |
| Mar 2023 | - | $556.04M(-198.8%) | $798.92M(+88.6%) |
| Dec 2022 | $423.69M(-70.4%) | -$563.08M(-310.6%) | $423.69M(-61.2%) |
| Sep 2022 | - | $267.39M(-50.4%) | $1.09B(-0.4%) |
| Jun 2022 | - | $538.56M(+197.9%) | $1.10B(-22.1%) |
| Mar 2022 | - | $180.82M(+69.9%) | $1.41B(-1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $1.43B(-24.0%) | $106.44M(-60.9%) | $1.43B(-17.5%) |
| Sep 2021 | - | $271.92M(-68.0%) | $1.73B(-18.3%) |
| Jun 2021 | - | $849.91M(+320.6%) | $2.12B(+10.9%) |
| Mar 2021 | - | $202.06M(-50.7%) | $1.92B(+1.8%) |
| Dec 2020 | $1.88B(-31.7%) | $410.27M(-38.0%) | $1.88B(-37.0%) |
| Sep 2020 | - | $661.49M(+3.1%) | $2.99B(+5.2%) |
| Jun 2020 | - | $641.90M(+281.1%) | $2.84B(+15.8%) |
| Mar 2020 | - | $168.41M(-88.9%) | $2.45B(-10.9%) |
| Dec 2019 | $2.75B(+50.4%) | $1.52B(+194.5%) | $2.75B(+122.4%) |
| Sep 2019 | - | $514.62M(+102.9%) | $1.24B(+71.1%) |
| Jun 2019 | - | $253.67M(-46.0%) | $723.63M(+54.0%) |
| Mar 2019 | - | $469.96M | $469.96M |
| Dec 2018 | $1.83B(+12.8%) | - | - |
| Dec 2017 | $1.62B | - | - |
FAQ
- What is Royalty Pharma annual EBITDA?
- What is the all time high annual EBITDA for Royalty Pharma?
- What is Royalty Pharma annual EBITDA year-on-year change?
- What is Royalty Pharma quarterly EBITDA?
- What is the all time high quarterly EBITDA for Royalty Pharma?
- What is Royalty Pharma quarterly EBITDA year-on-year change?
- What is Royalty Pharma TTM EBITDA?
- What is the all time high TTM EBITDA for Royalty Pharma?
- What is Royalty Pharma TTM EBITDA year-on-year change?
What is Royalty Pharma annual EBITDA?
The current annual EBITDA of RPRX is $1.56B
What is the all time high annual EBITDA for Royalty Pharma?
Royalty Pharma all-time high annual EBITDA is $2.75B
What is Royalty Pharma annual EBITDA year-on-year change?
Over the past year, RPRX annual EBITDA has changed by -$330.95M (-17.54%)
What is Royalty Pharma quarterly EBITDA?
The current quarterly EBITDA of RPRX is $498.69M
What is the all time high quarterly EBITDA for Royalty Pharma?
Royalty Pharma all-time high quarterly EBITDA is $1.52B
What is Royalty Pharma quarterly EBITDA year-on-year change?
Over the past year, RPRX quarterly EBITDA has changed by +$458.74M (+1148.01%)
What is Royalty Pharma TTM EBITDA?
The current TTM EBITDA of RPRX is $2.02B
What is the all time high TTM EBITDA for Royalty Pharma?
Royalty Pharma all-time high TTM EBITDA is $2.99B
What is Royalty Pharma TTM EBITDA year-on-year change?
Over the past year, RPRX TTM EBITDA has changed by +$643.87M (+46.96%)